Aminohippurate Sodium Inj 20% + CANAGLIFLOZIN for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Aug 2022: Trial registered, NCT05507892
  2. 10 Oct 2022: Trial started, NCT05507892

The trials

NCT05507892: Renal Mechanism of SGLT2 Inhibition

State
Under way
Phase
Phase 2
People
45 taking part
Started
10 Oct 2022
Primary completion
15 Dec 2026
Arms
Treatment
Results
None posted
  1. 19 Aug 2022: Trial registered
  2. 10 Oct 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.